Short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus (HIV) infection: an open, randomised, parallel group, multicentre phase II/III trial

Trial Profile

Short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus (HIV) infection: an open, randomised, parallel group, multicentre phase II/III trial

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Efavirenz (Primary) ; Abacavir; Didanosine; Emtricitabine; Lamivudine; Lamivudine/zidovudine; Nucleoside reverse transcriptase inhibitors; Stavudine; Tenofovir; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BREATHER; PENTA-16
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 16 Jul 2013 Planned End Date changed from 30 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top